Epifix denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for epifix are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied EpiFix: Experimental / Investigational

EpiFix (dehydrated human amnion/chorion membrane allograft) is a regenerative wound care product used for chronic wounds, including diabetic foot ulcers and venous leg ulcers. BCBS classifies treatments as "experimental or investigational" when, in its determination, there is insufficient evidence to establish clinical effectiveness for a specific indication. This is one of the most common — and most contested — denial categories for advanced wound care products, and it is frequently overturned on appeal because the evidence base for amniotic tissue allografts in chronic wound care has grown substantially.

## Why This Denial Is Appealable

An "experimental" classification is a clinical determination that an Independent Review Organization (IRO) can independently evaluate. External reviewers are not bound by BCBS's internal evidence threshold and apply their own assessment of the current medical literature and applicable clinical guideline organization positions. If your wound care specialist can document that EpiFix is consistent with accepted standards of care for your specific wound type, there is a strong basis for appeal, particularly at the external review level.

## Your Federal Appeal Rights

• Internal appeal: Under ACA Section 2719 and ERISA Section 503, you have the right to a full-and-fair internal review. File within the deadline in your denial letter.
• External review: Experimental/investigational denials are specifically subject to independent external review under ACA Section 2719. File with an IRO within approximately four months of exhausting internal remedies. This is often the most productive level for overturning experimental denials.
• Expedited review: If your wound poses an imminent risk of limb loss or serious infection, request expedited review at every level.

## Documentation to Gather

• Wound diagnosis and severity: Physician or specialist records confirming the wound type, duration, and severity, including wound measurements and staging.
• Prior treatment history with dates and outcomes: A detailed chronological record of all wound care treatments attempted before EpiFix, with specific dates and documented outcomes — this is essential to demonstrate that conventional options have been exhausted.
• Prescriber medical-necessity letter: A letter from your wound care specialist addressing why EpiFix is appropriate for your specific wound type and clinical situation, and referencing the applicable wound care guideline organization's position.
• Specialist credentials: Including the treating specialist's credentials strengthens the appeal, particularly for external review.

## Criteria-Mapping Structure

Request BCBS's medical policy for EpiFix to understand exactly how they define "experimental" for this product. Address each stated evidence criterion:

| BCBS Experimental Criterion | Your Response | |---|---| | Insufficient evidence of clinical effectiveness | Prescriber letter citing applicable guideline organization support | | Use not consistent with accepted standard of care | Specialist letter explaining how EpiFix fits the current wound care standard for your indication | | Required prior treatment failure not documented | Wound care records with dates and outcomes for all prior therapies |

For external review, your prescriber's letter should explicitly state whether treatment is consistent with the applicable wound care guideline organization's recommendations, as IROs weigh this heavily.